Literature DB >> 21890816

Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.

Shotaro Nakamura1, Toshiro Sugiyama, Takayuki Matsumoto, Katsunori Iijima, Shouko Ono, Masahiro Tajika, Akira Tari, Yasuhiko Kitadai, Hiroshi Matsumoto, Tadanobu Nagaya, Toshiro Kamoshida, Norihiko Watanabe, Toshimi Chiba, Hideki Origasa, Masahiro Asaka.   

Abstract

OBJECTIVE: A multicentre cohort follow-up study of a large number of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma was conducted to elucidate the long-term outcome of the disease after Helicobacter pylori eradication.
METHODS: 420 patients with gastric low-grade MALT lymphoma who had undergone successful H pylori eradication and been followed up for at least 3 years were registered from 21 participating institutes. Responders to treatment were defined as patients whose post-treatment biopsies showed complete histological response (ChR) or probable minimal residual disease (pMRD). Treatment failure was defined as the status of progressive disease or lymphoma relapse after ChR/pMRD.
RESULTS: 323 patients (77%) responded to H pylori eradication. A logistic regression analysis showed that absence of H pylori, submucosal invasion determined by endoscopic ultrasonography and t(11;18)/API2-MALT1 were independent predictors of resistance to H pylori eradication. During the follow-up periods ranging from 3.0 to 14.6 years (mean 6.5 years, median 6.04 years), the disease relapsed in 10 of 323 responders (3.1%) while progressive disease was found in 27 of 97 non-responders (27%). Thus, 37 of 420 patients (8.8%) were regarded as treatment failures. Of these 37 patients, transformation into diffuse large B cell lymphoma occurred in nine patients. Among the non-responders and relapsed patients, 17 patients were subjected to a 'watch and wait' strategy while 90 patients underwent second-line treatments including radiotherapy (n=49), chemotherapy (n=26), surgical resection (n=6), chemoradiotherapy (n=5), antibiotic treatment (n=2), rituximab monotherapy (n=1) or endoscopic resection (n=1). Probabilities of freedom from treatment failure, overall survival and event-free survival after 10 years were 90%, 95% and 86%, respectively. Cox multivariate analysis revealed endoscopic non-superficial type to be an independent prognostic factor for adverse freedom from treatment failure, overall survival and event-free survival.
CONCLUSIONS: The excellent long-term outcome of gastric MALT lymphoma after H pylori eradication was confirmed by this large-scale follow-up study.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890816     DOI: 10.1136/gutjnl-2011-300495

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  74 in total

Review 1.  Association between recurrent aphthous stomatitis and Helicobacter pylori infection: a meta-analysis.

Authors:  Lin Li; Huiyuan Gu; Guoxin Zhang
Journal:  Clin Oral Investig       Date:  2014-03-29       Impact factor: 3.573

Review 2.  Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review.

Authors:  Naoki Asano; Katsunori Iijima; Tomoyuki Koike; Akira Imatani; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

3.  Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

Authors:  Chelsea C Pinnix; Jillian R Gunther; Sarah A Milgrom; Ruben J Cruz Chamorro; L Jeffrey Medeiros; Joseph D Khoury; Behrang Amini; Sattva Neelapu; Hun J Lee; Jason Westin; Nathan Fowler; Loretta Nastoupil; Bouthaina Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-02-12       Impact factor: 7.038

4.  IgM monoclonal gammopathy in gastric MALToma.

Authors:  Zhineng J Yang; Gurprataap S Sandhu; Nidhi Aggarwal; Kenneth E Fasanella; Mounzer Agha
Journal:  J Gastrointest Cancer       Date:  2014-03

5.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

6.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

7.  Gastric malt lymphoma: Analysis of a series of consecutive patients over 20 years.

Authors:  Joana Moleiro; Sara Ferreira; Pedro Lage; A Dias Pereira
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

Review 8.  Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Authors:  Maike Buchner; Markus Müschen
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

Review 9.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

Review 10.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.